ATE157990T1 - Monoklonale antikörper gegen den humanen alpha/beta-t-zellenrezeptor, ihre herstellung und verwendung - Google Patents
Monoklonale antikörper gegen den humanen alpha/beta-t-zellenrezeptor, ihre herstellung und verwendungInfo
- Publication number
- ATE157990T1 ATE157990T1 AT90306178T AT90306178T ATE157990T1 AT E157990 T1 ATE157990 T1 AT E157990T1 AT 90306178 T AT90306178 T AT 90306178T AT 90306178 T AT90306178 T AT 90306178T AT E157990 T1 ATE157990 T1 AT E157990T1
- Authority
- AT
- Austria
- Prior art keywords
- beta
- monoclonal antibodies
- cell receptor
- antibodies against
- human alpha
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36254989A | 1989-06-07 | 1989-06-07 | |
| US52997990A | 1990-05-25 | 1990-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE157990T1 true ATE157990T1 (de) | 1997-09-15 |
Family
ID=27001722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT90306178T ATE157990T1 (de) | 1989-06-07 | 1990-06-07 | Monoklonale antikörper gegen den humanen alpha/beta-t-zellenrezeptor, ihre herstellung und verwendung |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0403156B1 (de) |
| JP (1) | JPH03219896A (de) |
| AT (1) | ATE157990T1 (de) |
| CA (1) | CA2018248A1 (de) |
| DE (1) | DE69031410T2 (de) |
| DK (1) | DK0403156T3 (de) |
| ES (1) | ES2109228T3 (de) |
| GR (1) | GR3025644T3 (de) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614192A (en) * | 1989-07-19 | 1997-03-25 | Connective Therapeutics, Inc. | T cell receptor peptides as therapeutics for immune-related disease |
| US5776459A (en) * | 1989-07-19 | 1998-07-07 | Connetics Corporation | TCR V beta 5 peptides |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB9020282D0 (en) | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
| GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| US5994510A (en) * | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
| FR2672901B1 (fr) * | 1991-02-15 | 1994-09-30 | Immunotech Sa | Nouvelles molecules de dna recombinants codant pour une chaine du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant. |
| DE4109884A1 (de) * | 1991-03-26 | 1992-10-01 | Claas Ohg | Steuerung einer verdraengermaschine eines hydrostatisch-mechanischen lastschaltgetriebes |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0590058B1 (de) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | Humanisierter Heregulin Antikörper |
| GB9325182D0 (en) * | 1993-12-08 | 1994-02-09 | T Cell Sciences Inc | Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions |
| JPH10509948A (ja) * | 1994-11-16 | 1998-09-29 | バクスター インターナショナル インコーポレイテッド | Ｔ細胞受容体ペプチドに対するヒト抗体およびそれらの調製方法 |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| CA2735193A1 (en) * | 2008-08-26 | 2010-03-11 | Macrogenics, Inc. | T-cell receptor antibodies and methods of use thereof |
| UY34317A (es) * | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| BR112014010532A2 (pt) | 2011-11-03 | 2017-04-18 | Tolera Therapeutics Inc | anticorpo e métodos para inibição seletiva de respostas de célula-t |
| US20130273089A1 (en) | 2011-11-03 | 2013-10-17 | Tolera Therapeutics, Inc. | Antibody and methods for selective inhibition of t-cell responses |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| US9580511B2 (en) | 2013-03-11 | 2017-02-28 | Genzyme Corporation | Site-specific antibody-drug conjugation through glycoengineering |
| CN106795220A (zh) * | 2013-10-30 | 2017-05-31 | 建新公司 | 通过αβTCR结合多肽的多重施用的用于增强免疫抑制疗法的方法 |
| HUE061339T2 (hu) | 2014-03-19 | 2023-06-28 | Genzyme Corp | Targetáló csoportok helyspecifikus glikotechnikai átalakítása |
| US10647768B2 (en) | 2014-05-29 | 2020-05-12 | Macrogenics, Inc. | Multi-chain polypeptide-containing tri-specific binding molecules |
| PL3204425T3 (pl) | 2014-10-09 | 2021-03-08 | Genzyme Corporation | Glikomodyfikowane koniugaty przeciwciał z lekami |
| WO2016059220A1 (en) | 2014-10-16 | 2016-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tcr-activating agents for use in the treatment of t-all |
| EP3220928B1 (de) * | 2014-11-20 | 2022-10-05 | UMC Utrecht Holding B.V. | Eine methode zur herstellung einer präparation, die mit manipulirten t-zellen mit exogenen immunrezeptoren angereichert ist |
| HRP20220890T1 (hr) * | 2015-02-06 | 2022-10-14 | National University Of Singapore | Postupci za povećanje učinkovitosti terapijskih imunosnih stanica |
| CN108367069B (zh) | 2015-12-14 | 2022-08-23 | 宏观基因有限公司 | 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 |
| AR108034A1 (es) | 2016-02-17 | 2018-07-11 | Macrogenics Inc | Moléculas de unión a ror1, y métodos de uso de las mismas |
| CN109069633A (zh) | 2016-04-15 | 2018-12-21 | 宏观基因有限公司 | 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法 |
| MX2018014950A (es) | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| ES2987986T3 (es) | 2016-06-10 | 2024-11-18 | Gadeta B V | Nuevo método para identificar cadenas de receptores de células T delta (o células T gamma) o partes de estas que intervienen en una respuesta antitumoral o antiinfecciosa |
| CN118581046A (zh) | 2016-11-22 | 2024-09-03 | 新加坡国立大学 | 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体 |
| BR112019012950A2 (pt) | 2016-12-23 | 2019-11-26 | Macrogenics, Inc. | molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo |
| US20190016802A1 (en) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Dual specificity polypeptide molecule |
| CA3071282A1 (en) | 2017-08-10 | 2019-02-14 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| EP3765517A1 (de) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | An calreticulin bindende multifunktionsmoleküle und ihre verwendungen |
| JP7584299B2 (ja) | 2018-05-23 | 2024-11-15 | ナショナル ユニバーシティ オブ シンガポール | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ２表面発現の遮断およびキメラ抗原受容体の発現 |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| GB201817172D0 (en) | 2018-10-22 | 2018-12-05 | Autolus Ltd | Antibody |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス，インコーポレーテッド | ＮＫｐ３０に結合する抗体分子およびその使用 |
| JP7575401B2 (ja) * | 2019-04-03 | 2024-10-29 | ジェンザイム・コーポレーション | 断片化が低減した抗アルファベータｔｃｒ結合ポリペプチド |
| WO2020201527A1 (en) | 2019-04-04 | 2020-10-08 | Umc Utrecht Holding B.V. | Modified immune receptor constructs |
| CN114729305A (zh) * | 2019-10-17 | 2022-07-08 | 苏州丹罗医药有限公司 | 用于免疫治疗的嵌合抗原受体、制备方法及其应用 |
| US20230054266A1 (en) * | 2019-12-30 | 2023-02-23 | Edigene Biotechnology Inc. | Method for purifying ucart cell and use thereof |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| CN113088495B (zh) * | 2020-01-09 | 2024-08-16 | 苏州方德门达新药开发有限公司 | 工程改造的t细胞、其制备及应用 |
| KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
| CN119233999A (zh) * | 2022-05-25 | 2024-12-31 | 羿尊生物医药（浙江）有限公司 | 靶向细胞膜受体蛋白的融合蛋白及其应用 |
| WO2026078231A1 (en) | 2024-10-11 | 2026-04-16 | T-Therapeutics Limited | Soluble non-aggregating immune ligand |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8720833D0 (en) * | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
-
1990
- 1990-06-05 CA CA002018248A patent/CA2018248A1/en not_active Abandoned
- 1990-06-07 AT AT90306178T patent/ATE157990T1/de not_active IP Right Cessation
- 1990-06-07 EP EP90306178A patent/EP0403156B1/de not_active Expired - Lifetime
- 1990-06-07 DE DE69031410T patent/DE69031410T2/de not_active Expired - Lifetime
- 1990-06-07 DK DK90306178.6T patent/DK0403156T3/da active
- 1990-06-07 ES ES90306178T patent/ES2109228T3/es not_active Expired - Lifetime
- 1990-06-07 JP JP2149725A patent/JPH03219896A/ja active Pending
-
1997
- 1997-12-10 GR GR970403296T patent/GR3025644T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2018248A1 (en) | 1990-12-07 |
| DK0403156T3 (da) | 1998-04-27 |
| EP0403156A1 (de) | 1990-12-19 |
| GR3025644T3 (en) | 1998-03-31 |
| EP0403156B1 (de) | 1997-09-10 |
| DE69031410T2 (de) | 1999-01-21 |
| DE69031410D1 (de) | 1997-10-16 |
| JPH03219896A (ja) | 1991-09-27 |
| ES2109228T3 (es) | 1998-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69031410D1 (de) | Monoklonale Antikörper gegen den humanen alpha/beta-T-Zellenrezeptor, ihre Herstellung und Verwendung | |
| DE68918497D1 (de) | Monoklonale Mäuseantikörper gegen HIV-IP24 und ihre Verwendung in Diagnostika. | |
| DE3750342D1 (de) | Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen. | |
| DE3588225D1 (de) | Anti-Lymphotoxin-Antikörper, Herstellung und Verwendung | |
| DE3787241D1 (de) | Monoklonale Antikörper gegen humanen Tumonekrosefaktor (TNF) und deren Verwendung. | |
| DE3852054D1 (de) | Monoklonale Antikörper gegen Glycolipid-Antigene und ihre Verwendung. | |
| DE69029015D1 (de) | Antikörper gegen menschlichen Interleukin-6-Rezeptor | |
| DE3751908D1 (de) | Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen | |
| DE69124387D1 (de) | Rahmenbau-mutierte antikörper und ihre herstellung | |
| ATE140486T1 (de) | Monoklonale antikörper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung | |
| NO901046D0 (no) | Rekombinat proteinreseptor. | |
| ATE159300T1 (de) | Monoklonale antikörper gegen menschliches ige | |
| ATE171473T1 (de) | Humanisierte monoklonale antikörper gegen humanes interleukin - 4 | |
| DE3682491D1 (de) | Immobilisierter c-peptid-antikoerper, seine herstellung und verwendung. | |
| DE3686766D1 (de) | Monoklonaler antikoerper gegen glutathion s-transferase und dessen verwendung zur diagnose von krebs. | |
| ATE109834T1 (de) | Monoklonaler antikörper spezifisch gegen humane pankreas-phospholipase-a2. | |
| DE3885975D1 (de) | Monoklonale Antikörper gegen menschliche alpha-Atrialnatriüretic-Polypeptide und entsprechende Hybridome, deren Herstellung und Verwendung. | |
| DE3673794D1 (de) | Monoklonale antikoerper gegen gamma-interferon, ihre herstellung und verwendung. | |
| DE3787239D1 (de) | Komplementabhängiger zytolytischer monoklonaler Antikörper gegen Trichomonas vaginalis und seine therapeutische und diagnostische Verwendung. | |
| DE69733051D1 (de) | Monoklonaler antikörper gegen ratte beta-2-integrin alpha d untereinheit und entsprechendes hybridoma | |
| ATE58397T1 (de) | Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen. | |
| DE3785175D1 (de) | A-assoziierte h-antigene, spezifische monoklonale antikoerper und methoden zu deren verwendung zur blutgruppenbestimmung. | |
| ATE144286T1 (de) | Monoklonale antikörper gegen den plasmin- antiplasmin komplex, verfahren zu ihrer herstellung sowie ihre verwendung | |
| DE3786130D1 (de) | Monoklonale antikoerper gegen oberflaechlichen ige-rezeptor, sowie hybrid-zellinien zu deren herstellung und verwendung. | |
| DE59310204D1 (de) | Spezifische Antikörper gegen aktivierte Plättchen, ihre Herstellung und ihre Verwendung in Diagnose und Therapie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEIH | Change in the person of patent owner | ||
| UEP | Publication of translation of european patent specification |
Ref document number: 0403156 Country of ref document: EP |
|
| EELA | Cancelled due to lapse of time |